BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 34814947)

  • 1. TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut.
    Gorecki AM; Anyaegbu CC; Anderton RS
    Transl Neurodegener; 2021 Nov; 10(1):47. PubMed ID: 34814947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Toll-like receptors influence Parkinson's disease in the microbiome-gut-brain axis.
    Zhang Z; Liu Z; Lv A; Fan C
    Front Immunol; 2023; 14():1154626. PubMed ID: 37207228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Toll-like receptors and neuroinflammation in Parkinson's disease.
    Heidari A; Yazdanpanah N; Rezaei N
    J Neuroinflammation; 2022 Jun; 19(1):135. PubMed ID: 35668422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease.
    Caputi V; Giron MC
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein induces prodromal symptoms of Parkinson's disease via activating TLR2/MyD88/NF-κB pathway in Schwann cells of vagus nerve in a rat model.
    Cheng Y; Tong Q; Yuan Y; Song X; Jiang W; Wang Y; Li W; Li Y; Zhang K
    J Neuroinflammation; 2023 Feb; 20(1):36. PubMed ID: 36788559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology.
    Dzamko N; Gysbers A; Perera G; Bahar A; Shankar A; Gao J; Fu Y; Halliday GM
    Acta Neuropathol; 2017 Feb; 133(2):303-319. PubMed ID: 27888296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.
    Dogra N; Mani RJ; Katare DP
    Cell Mol Neurobiol; 2022 Mar; 42(2):315-332. PubMed ID: 33649989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 4 deficiency facilitates α-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease.
    Venezia S; Kaufmann WA; Wenning GK; Stefanova N
    Parkinsonism Relat Disord; 2021 Oct; 91():59-65. PubMed ID: 34530328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice.
    Perez-Pardo P; Dodiya HB; Engen PA; Forsyth CB; Huschens AM; Shaikh M; Voigt RM; Naqib A; Green SJ; Kordower JH; Shannon KM; Garssen J; Kraneveld AD; Keshavarzian A
    Gut; 2019 May; 68(5):829-843. PubMed ID: 30554160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut-to-Brain α-Synuclein Transmission in Parkinson's Disease: Evidence for Prion-like Mechanisms.
    Chen M; Mor DE
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients.
    Doorn KJ; Moors T; Drukarch B; van de Berg WDj; Lucassen PJ; van Dam AM
    Acta Neuropathol Commun; 2014 Aug; 2():90. PubMed ID: 25099483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain-gut-microbiota axis in Parkinson's disease.
    Mulak A; Bonaz B
    World J Gastroenterol; 2015 Oct; 21(37):10609-20. PubMed ID: 26457021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysbiosis of the gut microbiota and its effect on α-synuclein and prion protein misfolding: consequences for neurodegeneration.
    Mahbub NU; Islam MM; Hong ST; Chung HJ
    Front Cell Infect Microbiol; 2024; 14():1348279. PubMed ID: 38435303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-
    Zhao Z; Li F; Ning J; Peng R; Shang J; Liu H; Shang M; Bao XQ; Zhang D
    Acta Pharm Sin B; 2021 Sep; 11(9):2859-2879. PubMed ID: 34589401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR4 and TLR2 activation is differentially associated with age during Parkinson's disease.
    Rocha Sobrinho HMD; Silva DJD; Gomides LF; Dorta ML; Oliveira MAP; Ribeiro-Dias F
    Immunol Invest; 2018 Jan; 47(1):71-88. PubMed ID: 29077524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroinflammation and protein pathology in Parkinson's disease dementia.
    Kouli A; Camacho M; Allinson K; Williams-Gray CH
    Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal Bacteria Maintain Adult Enteric Nervous System and Nitrergic Neurons via Toll-like Receptor 2-induced Neurogenesis in Mice.
    Yarandi SS; Kulkarni S; Saha M; Sylvia KE; Sears CL; Pasricha PJ
    Gastroenterology; 2020 Jul; 159(1):200-213.e8. PubMed ID: 32234538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of the Gut Microbiome in Parkinson's Disease.
    Elfil M; Kamel S; Kandil M; Koo BB; Schaefer SM
    Mov Disord; 2020 Jun; 35(6):921-933. PubMed ID: 32092186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.